31 across all subjects), education, recent drinking (drinks per week and drinking day, heavy drinking days defined as >3/>4 for women/men), scores on the AUDIT, age of first and regular drinking, gender, and percentage of smokers (see Table 1). Although all subjects denied using illicit drugs, two FHN subjects tested positive for cannabinoids on the placebo day, one of whom continued to test positive on the alcohol day. One FHP subject tested positive for amphetamines on both placebo and alcohol days, and a second FHP subject tested positive for amphetamines only on the alcohol day. This latter subject was excluded from analyses of the alcohol session data because of clear acute intoxication and the subject’s difficulty detecting odors on that day. No subject otherwise exhibited behavioral signs of intoxication in either session. One HD-FHN subject could not be used for the alcohol session because of excess movement. All subjects were right handed. All voluntarily signed informed consent statements approved by the Indiana University School of Medicine IRB.
